209 related articles for article (PubMed ID: 29635147)
21. Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration.
Le Tilly O; Azzopardi N; Bonneau C; Desvignes C; Oberkampf F; Ezzalfani M; Ternant D; Turbiez I; Gutierrez M; Paintaud G
Clin Pharmacol Ther; 2021 Jul; 110(1):210-219. PubMed ID: 33547646
[TBL] [Abstract][Full Text] [Related]
22. Intrathecal Trastuzumab as a Potential Cause of Drug-Induced Aseptic Meningitis.
Pappa E; Conforti R; Hoang-Xuan K; Alentorn A
Can J Neurol Sci; 2019 May; 46(3):358-359. PubMed ID: 30905325
[No Abstract] [Full Text] [Related]
23. A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.
Iyengar NM; Fornier MN; Sugarman SM; Theodoulou M; Troso-Sandoval TA; D'Andrea GM; Drullinsky PR; Gajria D; Goldfarb SB; Comen EA; Lake DE; Modi S; Traina TA; Lacouture ME; Chen MF; Patil S; Baselga J; Norton L; Hudis CA; Dang CT
Clin Breast Cancer; 2016 Apr; 16(2):87-94. PubMed ID: 26454612
[TBL] [Abstract][Full Text] [Related]
24. Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.
Tolaney S; Burris H; Gartner E; Mayer IA; Saura C; Maurer M; Ciruelos E; Garcia AA; Campana F; Wu B; Xu Y; Jiang J; Winer E; Krop I
Breast Cancer Res Treat; 2015 Jan; 149(1):151-61. PubMed ID: 25537644
[TBL] [Abstract][Full Text] [Related]
25. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F; Kattan JG; Ghosn M
Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
[TBL] [Abstract][Full Text] [Related]
26. Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience.
Figura NB; Long W; Yu M; Robinson TJ; Mokhtari S; Etame AB; Tran ND; Diaz R; Soliman H; Han HS; Sahebjam S; Forsyth PA; Ahmed KA
Breast Cancer Res Treat; 2018 Jun; 169(2):391-396. PubMed ID: 29392582
[TBL] [Abstract][Full Text] [Related]
27. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
[TBL] [Abstract][Full Text] [Related]
29. Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer.
Stemmler HJ; Schmitt M; Harbeck N; Willems A; Bernhard H; Lässig D; Schoenberg S; Heinemann V
Oncol Rep; 2006 May; 15(5):1373-7. PubMed ID: 16596213
[TBL] [Abstract][Full Text] [Related]
30. A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.
Hudis C; Swanton C; Janjigian YY; Lee R; Sutherland S; Lehman R; Chandarlapaty S; Hamilton N; Gajria D; Knowles J; Shah J; Shannon K; Tetteh E; Sullivan DM; Moreno C; Yan L; Han HS
Breast Cancer Res; 2013 Nov; 15(6):R110. PubMed ID: 24252402
[TBL] [Abstract][Full Text] [Related]
31. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
Chien AJ; Cockerill A; Fancourt C; Schmidt E; Moasser MM; Rugo HS; Melisko ME; Ko AH; Kelley RK; Korn WM; Esserman LJ; van't Veer L; Yau C; Wolf DM; Munster PN
Breast Cancer Res Treat; 2016 Feb; 155(3):521-30. PubMed ID: 26875185
[TBL] [Abstract][Full Text] [Related]
32. Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.
Boskovitz A; McLendon RE; Okamura T; Sampson JH; Bigner DD; Zalutsky MR
Nucl Med Biol; 2009 Aug; 36(6):659-69. PubMed ID: 19647172
[TBL] [Abstract][Full Text] [Related]
33. HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen.
Wu SA; Jia DT; Schwartz M; Mulcahy M; Guo K; Tate MC; Sachdev S; Kostelecky N; Escobar DJ; Brat DJ; Heimberger AB; Lukas RV
CNS Oncol; 2023 Sep; 12(3):CNS99. PubMed ID: 37219390
[TBL] [Abstract][Full Text] [Related]
34. Long-term complete response to intrathecal trastuzumab in a patient with leptomeningeal carcinomatosis due to her2- overexpressing breast cancer: Case report.
García FJV; Carrión NP; de la Cruz-Merino L
Medicine (Baltimore); 2020 Jan; 99(1):e18298. PubMed ID: 31895768
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
Yeo W; Luk MY; Soong IS; Yuen TY; Ng TY; Mo FK; Chan K; Wong SY; Tsang J; Leung C; Suen JJ; Ngan RK
Hong Kong Med J; 2018 Feb; 24(1):56-62. PubMed ID: 29326401
[TBL] [Abstract][Full Text] [Related]
36. A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
Reynolds KL; Bedard PL; Lee SH; Lin CC; Tabernero J; Alsina M; Cohen E; Baselga J; Blumenschein G; Graham DM; Garrido-Laguna I; Juric D; Sharma S; Salgia R; Seroutou A; Tian X; Fernandez R; Morozov A; Sheng Q; Ramkumar T; Zubel A; Bang YJ
BMC Cancer; 2017 Sep; 17(1):646. PubMed ID: 28899363
[TBL] [Abstract][Full Text] [Related]
37. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
38. Letter comments on EJC published article: Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2-positive breast carcinomatous meningitis.
Hofer S; Aebi S
Eur J Cancer; 2018 Nov; 103():279-280. PubMed ID: 30270111
[No Abstract] [Full Text] [Related]
39. A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.
Rimawi MF; Aleixo SB; Rozas AA; Nunes de Matos Neto J; Caleffi M; Figueira AC; Souza SC; Reiriz AB; Gutierrez C; Arantes H; Uttenreuther-Fischer MM; Solca F; Osborne CK
Clin Breast Cancer; 2015 Apr; 15(2):101-9. PubMed ID: 25537159
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results.
Perez EA; López-Vega JM; Petit T; Zamagni C; Easton V; Kamber J; Restuccia E; Andersson M
Breast Cancer Res; 2016 Dec; 18(1):126. PubMed ID: 27955684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
